P401 Long term effect of anti-TNFβ agents on the lipidemic profile of IBD patients

median age was 48 and median disease follow up was 6.5 years. Seventeen percent of were not on treatment; 36% on 5 ASA and 47% of patients were on effective immunosuppression. These included patients on thiopurines 40.3% (19), Methotrexate 4.2% (2) Infliximab 10.6% (5), Thiopurines +Infliximab 23.3% (11), Methotreaxte+Infliximab 2.1% (1), Adalimumab 4.2% (n = 2), Adalimumab+Thiopurines 2.1% (n = 1), Glucocorticoids 8.4% (4) and Infliximab + Prednisolone 4.2% (2). Immunization history was taken in 20% of the patients. Chest radiographs were performed in 42.5% (20) of patients, 25.5% were tested for Hepatitis B, 25.5% for Hepatitis C, 10.6% for HIV and 8.5% were tested for varicella titres. Cervical smears were performed in 19.2% (9) women. Of the patients on immunosuppressant 40.4% had no screening tests. Immunisation was carried out in 57.4% for Influenza, tetanus (38.3%), diphtheria (27.6%), pneumococcal (19.1%), meningococcus (10.6%), Hepatitis B (6.3%), HPV (6.3%) and MMR (17%). Twenty three percent of patients on immunosuppressants had no vaccinations. Conclusions: Our current practice was not in line with ECCO recommendations. IBD physicians must work in collaboration with primary care providers to ensure appropriate screening and vaccination in this vulnerable group. We have taken appropriate steps to ensure prompt screening of patients through a newly designed proforma.